Table of Content



Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Product
1.1.2 Phase
1.1.3 Indication
1.1.4 Regional Scope
1.1.5 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective - 1:
1.10.2 Objective - 2:
1.10.3 Objective - 3:
1.10.4 Objective - 4:
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Advanced Therapy Medicinal Products CDMO Market: Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rising number of clinical trials for ATMP
3.2.1.2 Increasing outsourcing activities
3.2.1.3 Growing awareness of the treatment
3.2.2 Market Restraint Analysis
3.2.2.1 Stringent regulatory approvals
3.2.2.2 High cost of outsourcing
3.3 Penetration & Growth Prospect Mapping
3.4 Advanced Therapy Medicinal Products CDMO: Market Analysis Tools
3.4.1 Industry Analysis - Porter’s
3.4.1.1 Porter’s Five Forces Analysis
3.4.2 PESTEL Analysis
Chapter 4 Advanced Therapy Medicinal Products CDMO Market: Product Estimates
4.1 Market Share Analysis, 2020 & 2028
4.2 Gene Therapy
4.2.1 Gene therapy market, 2016 - 2028 (USD Billion)
4.3 Cell Therapy
4.3.1 Cell therapy market, 2016 - 2028 (USD Billion)
4.4 Tissue Engineered
4.4.1 Tissue engineered market, 2016 - 2028 (USD Billion)
4.5 Others
4.5.1 Market, 2016 - 2028 (USD Billion)
Chapter 5 Advanced Therapy Medicinal Products CDMO Market: Phase Estimates
5.1 Market Share Analysis, 2020 & 2028
5.2 Phase I
5.2.1 Phase I market, 2016 - 2028 (USD Billion)
5.3 Phase II
5.3.1 Phase II market, 2016 - 2028 (USD Billion)
5.4 Phase III
5.4.1 Phase III market, 2016 - 2028 (USD Billion)
5.5 Phase IV
5.5.1 Phase IV market, 2016 - 2028 (USD Billion)
Chapter 6 Advanced Therapy Medicinal Products CDMO Market: Indication Estimates
6.1 Market Share Analysis, 2020 & 2028
6.2 Oncology
6.2.1 Oncology market, 2016 - 2028 (USD Billion)
6.3 Cardiology
6.3.1 Cardiology market, 2016 - 2028 (USD Billion)
6.4 Central Nervous System
6.4.1 Central nervous system market, 2016 - 2028 (USD Billion)
6.5 Musculoskeletal
6.5.1 Musculoskeletal market, 2016 - 2028 (USD Billion)
6.6 Infectious Disease
6.6.1 Infectious disease market, 2016 - 2028 (USD Billion)
6.7 Dermatology
6.7.1 Dermatology market, 2016 - 2028 (USD Billion)
6.8 Endocrine, Metabolic, Genetic
6.8.1 Endocrine, metabolic, genetic market, 2016 - 2028 (USD Billion)
6.9 Immunology & inflammation
6.9.1 Immunology & inflammation market, 2016 - 2028 (USD Billion)
6.10 Ophthalmology
6.10.1 Ophthalmology market, 2016 - 2028 (USD Billion)
6.11 Haematology
6.11.1 Haematology market, 2016 - 2028 (USD Billion)
6.12 Gastroenterology
6.12.1 Gastroenterology market, 2016 - 2028 (USD Billion)
6.13 Others
6.13.1 Others market, 2016 - 2028 (USD Billion)
Chapter 7 Advanced Therapy Medicinal Products CDMO Market: Regional Analysis
7.1 Advanced Therapy Medicinal Products CDMO: Regional Market Share Analysis, 2020 & 2028
7.2 North America
7.2.1 North America Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.2.2 U.S.
7.2.2.1 U.S. Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.2.3 Canada
7.2.3.1 Canada Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.3 Europe
7.3.1 Europe Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.3.2 U.K.
7.3.2.1 U.K. Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.3.3 Germany
7.3.3.1 Germany Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.3.4 France
7.3.4.1 France Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.3.5 Italy
7.3.5.1 Italy Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.3.6 Spain
7.3.6.1 Spain Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.4 Asia Pacific
7.4.1 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.4.2 China
7.4.2.1 China Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.4.3 Japan
7.4.3.1 Japan Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.4.4 India
7.4.4.1 India Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.4.5 Australia
7.4.5.1 Australia Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.4.6 South Korea
7.4.6.1 South Korea Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.5 Latin America
7.5.1 Latin America Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.5.2 Brazil
7.5.2.1 Brazil Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.5.3 Mexico
7.5.3.1 Mexico Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.5.4 Argentina
7.5.4.1 Argentina Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.5.5 Colombia
7.5.5.1 Colombia Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.5.6 Chile
7.5.6.1 Chile Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.6 MEA
7.6.1 MEA Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.6.2 South Africa
7.6.2.1 South Africa Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.6.4 UAE
7.6.4.1 UAE Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.6.5 Israel
7.6.5.1 Israel Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.6.6 Egypt
7.6.6.1 Egypt Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
Chapter 8 Company Profiles
8.1 Strategic Framework
8.2 Company Profiles
8.2.1 Celonic
8.2.1.1 Company overview
8.2.1.2 Financial performance
8.2.1.3 Product Benchmarking
8.2.1.5 Strategic initiatives
8.2.2 Bio Elpida
8.2.2.1 Company overview
8.2.2.2 Financial performance
8.2.2.3 Product benchmarking
8.2.2.6 Strategic initiatives
8.2.3 CGT Catapult
8.2.3.1 Company Overview
8.2.3.2 Financial performance
8.2.3.3 Product Benchmarking
8.2.3.6 Strategic initiatives
8.2.4 Rentschler Biopharma SE
8.2.4.1 Company Overview
8.2.4.2 Financial performance
8.2.4.3 Product Benchmarking
8.2.4.6 Strategic initiatives
8.2.5 AGC Biologics
8.2.5.1 Company overview
8.2.5.2 Financial performance
8.2.5.3 Product benchmarking
8.2.5.6 Strategic initiatives
8.2.6 Catalent
8.2.6.1 Company Overview
8.2.6.2 Financial performance
8.2.6.3 Product Benchmarking
8.2.6.6 Strategic initiatives
8.2.7 Lonza
8.2.7.1 Company Overview
8.2.7.2 Financial Performance
8.2.7.3 Product benchmarking
8.2.7.5 Strategic initiatives
8.2.8 WuXi Advanced Therapies
8.2.8.1 Company Overview
8.2.8.2 Financial performance
8.2.8.3 Product benchmarking
8.2.8.5 Strategic initiatives
8.2.9 BlueReg
8.2.9.1 Company overview
8.2.9.2 Financial performance
8.2.9.3 Product benchmarking
8.2.9.6 Strategic initiatives
8.2.10 Minaris Regenerative Medicine
8.2.10.1 Company overview
8.2.10.2 Financial performance
8.2.10.3 Product benchmarking
8.2.10.5 Strategic initiatives
8.2.11 Patheon
8.2.11.1 Company overview
8.2.11.2 Financial performance
8.2.11.3 Product benchmarking
8.2.11.5 Strategic initiatives



List of Figures

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Volume Price Analysis
Fig. 10 Advanced therapy medicinal products CDMO market snapshot (2020)
Fig. 11 Advanced therapy medicinal products CDMO market segmentation
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Porter’s five forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 Advanced therapy medicinal products CDMO market product outlook: Segment dashboard
Fig. 18 Advanced therapy medicinal products CDMO market: Product movement analysis
Fig. 19 Gene therapy market, 2016 - 2028 (USD Billion)
Fig. 20 Cell therapy market, 2016 - 2028 (USD Billion)
Fig. 21 Tissue engineered market, 2016 - 2028 (USD Billion)
Fig. 22 Others (Combined ATMPs, for example biodegradable matric or scaffold) market, 2016 - 2028 (USD Billion)
Fig. 23 Advanced therapy medicinal products CDMO market phase outlook: Segment dashboard
Fig. 24 Advanced therapy medicinal products CDMO market: Phase movement analysis
Fig. 25 Phase I market, 2016 - 2028 (USD Billion)
Fig. 26 Phase II market, 2016 - 2028 (USD Billion)
Fig. 27 Phase III market, 2016 - 2028 (USD Billion)
Fig. 28 Phase IV market, 2016 - 2028 (USD Billion)
Fig. 29 Advanced therapy medicinal products CDMO market indication outlook: Segment dashboard
Fig. 30 Advanced therapy medicinal products CDMO market: Indication movement analysis
Fig. 31 Oncology market, 2016 - 2028 (USD Billion)
Fig. 32 Cardiology market, 2016 - 2028 (USD Billion)
Fig. 33 Central nervous system market, 2016 - 2028 (USD Billion)
Fig. 34 Musculoskeletal market, 2016 - 2028 (USD Billion)
Fig. 35 Infectious disease market, 2016 - 2028 (USD Billion)
Fig. 36 Dermatology market, 2016 - 2028 (USD Billion)
Fig. 37 Endocrine, metabolic, genetic market, 2016 - 2028 (USD Billion)
Fig. 38 Immunology & inflammation market, 2016 - 2028 (USD Billion)
Fig. 39 Ophthalmology market, 2016 - 2028 (USD Billion)
Fig. 40 Haematology market, 2016 - 2028 (USD Billion)
Fig. 41 Gastroenterology market, 2016 - 2028 (USD Billion)
Fig. 42 Others market, 2016 - 2028 (USD Billion)
Fig. 43 Regional market: Key takeaways
Fig. 44 Regional outlook, 2020 & 2028
Fig. 45 North America market, 2016 - 2028 (USD Billion)
Fig. 46 U.S. market, 2016 - 2028 (USD Billion)
Fig. 47 Canada market, 2016 - 2028 (USD Billion)
Fig. 48 Europe market, 2016 - 2028 (USD Billion)
Fig. 49 U.K. market, 2016 - 2028 (USD Billion)
Fig. 50 Germany market, 2016 - 2028 (USD Billion)
Fig. 51 France market, 2016 - 2028 (USD Billion)
Fig. 52 Italy market, 2016 - 2028 (USD Billion)
Fig. 53 Spain market, 2016 - 2028 (USD Billion)
Fig. 54 Asia Pacific market, 2016 - 2028 (USD Billion)
Fig. 55 China market, 2016 - 2028 (USD Billion)
Fig. 56 Japan market, 2016 - 2028 (USD Billion)
Fig. 57 India market, 2016 - 2028 (USD Billion)
Fig. 58 Australia market, 2016 - 2028 (USD Billion)
Fig. 59 South Korea market, 2016 - 2028 (USD Billion)
Fig. 60 Latin America market, 2016 - 2028 (USD Billion)
Fig. 61 Brazil market, 2016 - 2028 (USD Billion)
Fig. 62 Mexico market, 2016 - 2028 (USD Billion)
Fig. 63 Argentina market, 2016 - 2028 (USD Billion)
Fig. 64 Colombia market, 2016 - 2028 (USD Billion)
Fig. 65 Chile market, 2016 - 2028 (USD Billion)
Fig. 66 MEA market, 2016 - 2028 (USD Billion)
Fig. 67 South Africa market, 2016 - 2028 (USD Billion)
Fig. 68 Saudi Arabia market, 2016 - 2028 (USD Billion)
Fig. 69 UAE market, 2016 - 2028 (USD Billion)
Fig. 70 Israel market, 2016 - 2028 (USD Billion)
Fig. 71 Egypt market, 2016 - 2028 (USD Billion)
Fig. 72 Strategic Framework